Recombinant Human BTN3A2 His-tag Avi-tag Protein, CF

2 μg/lane of Recombinant Human BTN3A2 His-tag Avi-tag (Catalog # AVI9514) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 27-37 kDa.

When Sheep Anti-Human BTN3A1/2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF7136) is immobilized at 1.0 μg/mL, 100 μL/well, the concentration of Biotinylated Recombinant Human BTN3A2 His-tag Avi-tag (Catalog # AVI9514) that produces 50% of the optimal binding response is approximately 15-75 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human BTN3A2 His-tag Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Sheep Anti-Human BTN3A1/2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF7136) is immobilized at 1.0 μg/mL, 100 μL/well, the concentration of Biotinylated Recombinant Human BTN3A2 His-tag Avi-tag (Catalog # AVI9514) that produces 50% of the optimal binding response is approximately 15-75 ng/mL. Measured by its ability to enhance anti-CD3-induced IFN-gamma secretion of mouse CD3⁺ T cells. The ED₅₀ for this effect is 1.5-9.0 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human BTN3A2 protein
  

  Human BTN3A2 (Gln30-Trp248) Accession # P78410-1	HHHHHH	Avi-tag
  N-terminus		C-terminus

• Accession #: P78410-1
• Structure / Form: Biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Bioactivity2
• Theoretical MW: 26 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 27-37 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human BTN3A2 His-tag Avi-tag Protein, CF

• BT3.2
• BT3.3
• BTF3
• BTF4
• BTF4butyrophilin protein
• BTN3A2
• butyrophilin subfamily 3 member A2
• butyrophilin, subfamily 3, member A2
• FLJ40011

Background

BTN3A2 (Butyrophilin subfamily 3 member A2; also BTF3 and BT3.2) is a 36 kDa (predicted) glycoprotein, member of the BTN family, Ig Superfamily of molecules. It is postulated to be expressed on immune-related cells, as it has a structural similarity to MHC and CD80/CD86 molecules. Mature human BTN3A2 is a 305 amino acid (aa) type I transmembrane protein. It contains a 219 aa extracellular region with one V-type Ig-like domain and a 65 aa cytoplasmic tail. The cytoplasmic region undergoes phosphorylation on two serines. There are three potential splice forms. A rodent counterpart to BTN3A2 has not been reported. BTN3A2 mRNA over‑expression was associated with a good prognosis in relation to disease-free and overall survival in a cohort of 55 epithelial ovarian cancer (EOC) patients (1). Another study in a larger cohort of 199 high-grade EOC patients further confirmed that the protein expression of BTN3A2 in ovarian cancer tissues is positively correlated with the intraepithelial infiltration of CD4⁺ and CD8⁺ T cells (2), suggesting that BTN3A2 was a co-stimulatory molecule to modulate the infiltration of immune cells and thus the anti-cancer immunity. In consistent with previous publications, our in-house studies on BTN3A2 showed that BTN3A2 co-stimulated anti‑CD3 induced IFN-gamma secretion on CD3⁺ cells.

1. LePage C., et al. Cancer Epidemiol Biomarkers Prev (2008) 17:913.
2. LePage C., et al. PLoSOne (2012) 7:e38541.

Bioinformatics

• Uniprot:
  • P78410-1()